1-[(4-chlorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid | 116404-24-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-[(4-chlorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid
• 英文别名: 1-<(4-Chlorphenyl)methyl>-5-oxoprolin；N-(4-chlorobenzyl)pyroglutamic acid
• CAS: 116404-24-1
• 化学式: C₁₂H₁₂ClNO₃
• 分子量: 253.685
• InChiKey: BCZYCMUPDFSLAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(4-chlorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid 在 三氯化铝 、 氯化亚砜 作用下， 以67%的产率得到8-chloro-1,10a-dihydropyrrolo[1,2-b]isoquinoline-3,10[2H,5H]-dione
  参考文献：
  名称：

  由吡咯并[1,2- b ]异喹啉合成新型1,2,3,4-四氢苯并[ c ] -1,5-萘啶

  摘要：

  1,2,3,4-四氢苯并[ c ] -1,5-萘啶（5a）是通过涉及（±）-（Z）-1,10a-二氢吡咯并[1,2- b ]异喹啉-3,10（2 H，5 H）-二酮肟制得1,4-二氢苯并[ c ] -1,5-萘啶-2（3 H）-一，还原为5a。用5a观察到的拟胆碱活性促使其他类似物的合成和生物学评估。

  DOI：

  10.1002/jhet.5570240609
• 作为产物：
  描述：

  1-<(4-Chlorphenyl)methyl>-5-oxoprolin-methylester 在 sodium hydroxide 作用下， 以81%的产率得到1-[(4-chlorophenyl)methyl]-5-oxopyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  Effenberger, Franz; Mueller, Wolfgang; Isak, Heinz, Chemische Berichte, 1987, vol. 120, p. 45 - 54

  摘要：

  DOI：

文献信息

• [EN] 3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS<br/>[FR] CARBOXAMIDES DE 3,7-DIAZABICYCLO[3.3.1]NONANE À TITRE D'AGENTS ANTITHROMBOTIQUES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015044951A1

  公开（公告）日：2015-04-02

  The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

  本发明涉及3,7-二氮杂双环[3.3.1]壬烷羧酰胺及其制备方法。本发明还涉及具有抗血栓（抗血小板）活性的一般式（1）化合物。该发明还涉及将这些基团用作体外和体内介导的胶原受体抑制剂，抑制胶原诱导的血小板粘附和聚集。此外，该发明还涉及这类化合物通过双重机制表现出抗血小板功效，既抑制了胶原又抑制了U46619（血栓素受体激动剂）诱导的血小板聚集。一般式（1）中，其中，R'为；其中R选自烷基、酰基、对甲苯磺酰基、叔丁氧羰基、芳基烷基或取代芳基烷基；R''优选选自卤素、氰基、低烷基、芳基、取代芳基和对甲苯磺基；R1选自氢和低烷基；R2选自低烷基和芳基；R3选自叔丁氧羰基和苯甲氧羰基；n = 0,1。
• Studies on pyrrolidinones. Synthesis of some bioisosteres of 3,3,5-trimethylcyclohexyl pyroglutamate
  作者：Benoǐt Rigo、Claude Laruelle

  DOI：10.1002/jhet.5570340142

  日期：1997.1

  The synthesis of new N-(4-chlorobenzyl) and N-(4-chlorobenzoyl)pyroglutamic esters and amids whose the structure conserves the main structural features of the cholesterol lowering agent crilvastatin is described.

  描述了新的N-（4-氯苄基）和N-（4-氯苯甲酰基）焦谷氨酸酯和酰胺的合成，其结构保留了降胆固醇剂crilvastatin的主要结构特征。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HAPLOGEN GMBH

  公开号：WO2018050631A1

  公开（公告）日：2018-03-22

  The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

  本发明涉及一般式（I）的新化合物，其中X和R1至R4基团的含义如描述和索赔中所述，制备这些化合物的方法以及它们作为治疗、预防或改善病毒感染的用途，以及用于治疗、预防或改善与PLA2G16相关的疾病的用途。
• Studies on pyrrolidinones. Synthesis of 2-(5-oxo-2-pyrrolidinyl)-1,3,4-oxadiazoles and 2-(5-oxo-2-pyrrolidinyl)benzimidazoles
  作者：Pascal Cauliez、Daniel Couturier、Benoît Rigo、Dominique Fasseur、Patrice Halama

  DOI：10.1002/jhet.5570300414

  日期：1993.7

  The condensation of pyroglutamic acids with 1,2-phenylenediamine leads to 2-(5-oxo-2-pyrrolidinyl)benzimidazoles and the cyclization of disilylated diacylhydrazines derived from the same acids gives 2-(5-oxo-2-pyrrolidinyl)-1,3,4-oxadiazoles. These compounds show weak antifungal activity.

  焦谷氨酸与1,2-苯二胺的缩合反应生成2-（5-氧代-2-吡咯烷基）苯并咪唑，衍生自相同酸的二烯丙基化二酰基肼的环化生成2-（5-氧代-2-吡咯烷基）-1 ，3,4-恶二唑。这些化合物显示出弱的抗真菌活性。
• A Convenient Method for the Conversion of a Carboxy Group into a 4,6-Di­methoxy-1,3,5-triazine Group: Application to <i>N</i>-Benzylpyroglutamic Acids
  作者：Philippe Gautret、Souhila Oudir、Benoît Rigo、Jean-Pierre Hénichart

  DOI：10.1055/s-2006-942519

  日期：2006.9

  Reaction of an activated form of carboxylic acids with a stoichiometric amount of zinc dimethyl imidodicarbonimidate (in CH2Cl2-pyridine with molecular sieves), led to 4,6-dimethoxy-1,3,5-triazines in high yields. This method has been applied to N-benzylpyroglutamic acids, in the preparation of potential antifungal products.

  将活化形式的羧酸与一定量的二甲基亚氨基二甲酰亚胺锌（在带有分子筛的 CH2Cl2 吡啶中）反应，可以高产率地制备出 4,6-二甲氧基-1,3,5-三嗪。这种方法已被应用于 N-苄基焦谷氨酸，以制备潜在的抗真菌产品。